A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant

Clinical Infectious Diseases

Volumn 58, Issue 6, 2014, Pages 785-803

  Florescu, Diana F ^a,b   Qiu, Fang ^c   Schmidt, Cynthia M ^a   Kalil, Andre C ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b Transplant Surgery Division Department of General Surgery   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

cytomegalovirus; efficacy; meta analysis; preemptive; prophylaxis

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VALACICLOVIR; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ARTICLE; BACTERIAL INFECTION; CHEMOPROPHYLAXIS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; GRAFT FAILURE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; LEUKOPENIA; META ANALYSIS; MYCOSIS; NEUTROPENIA; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SURGICAL MORTALITY; SURGICAL PATIENT; VIREMIA; ADULT; ANTIBIOTIC PROPHYLAXIS; CYTOMEGALOVIRUS INFECTIONS; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; PROCEDURES; RISK;

ADULT; ANTIBIOTIC PROPHYLAXIS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOSUPPRESSION; MIDDLE AGED; ODDS RATIO; ORGAN TRANSPLANTATION;

EID: 84895748068     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit945     Document Type: Article

References (63)

1. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870-80
2. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20
3. Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009; 28:670-5
4. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10:1228-37
5. Humar A, Snydman D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4):S78-86
6. Viechtbauer W. Conductin meta-analyses in R with the metafor package. J Stat Softw 2010; 36:1-48. Available at: http://www.jstatsoft.org/ v36/i03/. Accessed 15 February 2013
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-88
8. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 20:13
9. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50:683-91
10. Bodro M, Sabe N, Llado L, et al. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transpl 2012; 18:1093-9
11. Couzi L, Helou S, Bachelet T, et al. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction. Transplant Proc 2012; 44:2809-13
12. Kim SI, Kim CJ, Kim YJ, et al. Antiviral prophylaxis versus preemptive therapy to prevent cytomegalovirus infection and related death in liver transplantation: a retrospective study with propensity score matching. Transplant Proc 2012; 44:787-90
13. Witzke O, Hauser IA, Bartels M, et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012; 93:61-8
14. Abate D, Saldan A, Fiscon M, et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010; 202:585-94
15. McGillicuddy JW, Weimert NA, Taber DJ, et al. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk? Transplantation 2010; 89:1218-23
16. van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010; 89:320-6
17. Lopez-Medrano F, Rueda B, Lizasoain M, et al. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreaskidney transplant recipients. Transpl Infect Dis 2009; 11:400-4
18. Paudice N, Mehmetaj A, Zanazzi M, et al. Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience. Transplant Proc 2009; 41:1204-6
19. Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2009; 28:461-7
20. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8:69-77
21. Diaz-Pedroche C, Lumbreras C, San Juan R, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006; 82:30-5
22. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6:2134-43
23. Monforte V, Roman A, Gavalda J, et al. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients. Transplant Proc 2005; 37:4039-42
24. Singh N, Yu VL, Mieles L,Wagener MM, Miner RC, Gayowski T. Highdose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994; 120:375-81
25. Jung C, Engelmann E, Borner K, Offermann G. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc 2001; 33:3621-3
26. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8:975-83
27. Qiu J, Chen L, Li J, et al. Prospective study of pre-empty prophylaxis strategy combined with recipients' risk-factors to prevent CMV disease after kidney transplantation. Chin J Organ Transplant 2008; 29: 294-297
28. Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation 2007; 83:874-82
29. Weclawiak H, Kamar N, Mengelle C, et al. Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirusseropositive kidney-transplant recipients. Transpl Int 2010; 23:1056-64
30. Rayes N, Seehofer D, Schmidt CA, et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation 2001; 72:881-5
31. Sagedal S, Nordal KP, Hartmann A, et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003; 18:1899-908
32. Torre-Cisneros J, Madueno JA, Herrero C, et al. Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. Clin Microbiol Infect 2002; 8:773-80
33. Paya CV,Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185:854-60
34. Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirus- associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8:118-25
35. Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch Surg 1995; 130:1217-21; discussion 1221-2
36. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123:18-26
37. Koetz AC, Delbruck R, Furtwangler A, et al. Cytomegalovirus pp65 antigen- guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study. Transplantation 2001; 72:1325-7
38. Snydman DR, Falagas ME, Avery R, et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMVseronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc 2001; 33: 2571-5
39. Leone F, Akl A, Giral M, et al. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation. Transpl Int 2010; 23:897-906
40. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. international valacyclovir cytomegalovirus prophylaxis transplantation study group. N Engl J Med 1999; 340:1462-70
41. Barkholt L, Lewensohn-Fuchs I, Ericzon BG, Tyden G, Andersson J. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transpl Infect Dis 1999; 1:89-97
42. Gavalda J, de Otero J, Murio E, et al. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transpl Int 1997; 10:462-5
43. Rostaing L, Crespin A, Icart J, et al. Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients. Transpl Int 1994; 7(suppl 1):S331-5
44. Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64:1843-6
45. Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7:325-30
46. Pouteil-Noble C, Megas F, Chapuis F, et al. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Transplant Proc 1996; 28:2811
47. Saliba F, Eyraud D, Samuel D, et al. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc 1993; 25(1 pt 2):1444-5
48. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350:1729-33
49. Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320:1381-7
50. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis 2011; 52:313-21
51. Zhang LF, Wang YT, Tian JH, Yang KH, Wang JQ. Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials. Transpl Infect Dis 2011; 13:622-32
52. Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13(suppl 4):93-106
53. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78:1390-6
54. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46:840-6
55. Pang XL, Fox JD, Fenton JM, et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009; 9:258-68
56. Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis 2012; 54:1793-7
57. Jones BC, Logsdon NJ, Josephson K, Cook J, Barry PA, Walter MR. Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc Natl Acad Sci U S A 2002; 99:9404-9
58. Spencer JV, Lockridge KM, Barry PA, et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 2002; 76:1285-92
59. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103:106-13
60. Gorensek MJ, Stewart RW, Keys TF, McHenry MC, Babiak T, Goormastic M. Symptomatic cytomegalovirus infection as a significant risk factor for major infections after cardiac transplantation. J Infect Dis 1988; 158:884-7
61. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidencebased reassessment of safety and efficacy. PLoS One 2009; 4:e5512
62. Borchers AT, Perez R, Kaysen G, Ansari AA, Gershwin ME. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol 1999; 7:75-82
63. Walker JD, Maier CL, Pober JS. Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic exosomes. J Immunol 2009; 182:1548-59